Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 4Gastrointestinal 4Tumor-Agnostic 3Head & Neck 2Gynecologic 2CNS 2Thoracic 1Sarcoma 1Plasma cell 1Lymphoid 1Dermatologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Nasopharyngeal Neoplasms 1Epstein-Barr Virus Infections 1Anal Canal Carcinoma 1

Interventions

Cisplatin 315Radiotherapy 139Cetuximab 133pembrolizumab 131Docetaxel 122Carboplatin 119Radiotherapy, Intensity-Modulated 97Fluorouracil 94Paclitaxel 92Nivolumab 64Gemcitabine 50toripalimab 46Radiation 44Drug Therapy 39Capecitabine 39Magnetic Resonance Spectroscopy 38Surgical Procedures, Operative 33camrelizumab 31130-nm albumin-bound paclitaxel 29apatinib 27tislelizumab 26Chemoradiotherapy 26Specimen Handling 25Bevacizumab 24durvalumab 23Albumin-Bound Paclitaxel 23nimotuzumab 22lenvatinib 21Sorafenib 21Platinum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Vaccines × Head & Neck × Clear all
NCT03946358 2024-12-20

VolATIL

Centre Hospitalier Universitaire de Besancon

Phase 2 Completed
47 enrolled
GastrointestinalGynecologicHead & Neck

Anal Canal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms

NCT01094405 2021-07-28

Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy

Chinese University of Hong Kong

Phase 2 Completed
25 enrolled
Head & Neck

Nasopharyngeal Neoplasms, Recurrence, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡